Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
February 1, 2026
Katarzyna Kała, Dorota Bederska‐łojewska, Jan Lazur et al.
The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the form of fungal fruiting bodies, this...
The International Journal of Neuropsychopharmacology
August 1, 2025
Yana Babii, C. Barbara, Dorota Bederska‐łojewska et al.
Abstract Background Numerous data indicates that hallucinogens from various groups such as ketamine, scopolamine or psilocybin exert rapid antidepressant effects in both preclinical and clinical studies. Group II glutamate (mGlu) metabotropic receptor antagonists also show rapid antidepressant efficacy in animal studies, moreover we have shown that mGluR2/3 antagonist, LY341495 is able to...
Pharmacological Reports
December 1, 2023
Barbara Chruścicka-Smaga, Agata Machaczka, Bernadeta Szewczyk et al.
2 citations
The desire to find a gold-standard therapy for depression is still ongoing. Developing one universal and effective pharmacotherapy remains troublesome due to the high complexity and variety of symptoms. Over the last decades, the understanding of the mechanism of pathophysiology of depression and its key consequences for brain functioning have undergone significant changes, referring to the...
Expert Opinion on Investigational Drugs
August 17, 2022
Bartłomiej Pochwat, A. Krupa, M. Siwek et al.
ABSTRACT Introduction Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness. Ketamine, with its rapid action and long-lasting effects, represents a breakthrough in the modern pharmacotherapy of depression. Areas covered The current review summarizes the latest findings on the mechanism of the antidepressant...
Frontiers in Molecular Neuroscience
2018
Bartłomiej Pochwat, Bernadeta Szewczyk, Katarzyna Kotarska et al.
N-methyl-D-aspartate receptor (NMDAR) modulators induce rapid and sustained antidepressant like-activity in rodents through a molecular mechanism of action that involves the activation of Ca2+ dependent signaling pathways. Moreover, ketamine, a global NMDAR antagonist is a potent, novel, and atypical drug that has been successfully used to treat major depressive disorder (MDD). However, because...